Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 599

1.

Association between phenotypic familial hypercholesterolaemia and telomere length in US adults: results from a multi-ethnic survey.

Banach M, Mazidi M, Mikhailidis DP, Toth PP, Jozwiak J, Rysz J, Watts GF.

Eur Heart J. 2018 Aug 28. doi: 10.1093/eurheartj/ehy527. [Epub ahead of print]

PMID:
30165413
2.

Simplified Canadian Definition for Familial Hypercholesterolemia.

Ruel I, Brisson D, Aljenedil S, Awan Z, Baass A, Bélanger A, Bergeron J, Bewick D, Brophy JM, Brunham LR, Couture P, Dufour R, Francis GA, Frohlich J, Gagné C, Gaudet D, Grégoire JC, Gupta M, Hegele RA, Mancini GBJ, McCrindle BW, Pang J, Raggi P, Tu JV, Watts GF, Genest J.

Can J Cardiol. 2018 Sep;34(9):1210-1214. doi: 10.1016/j.cjca.2018.05.015. Epub 2018 May 19.

PMID:
30093300
3.

In search of the vulnerable patient or the vulnerable plaque: 18F-sodium fluoride positron emission tomography for cardiovascular risk stratification.

Bellinge JW, Francis RJ, Majeed K, Watts GF, Schultz CJ.

J Nucl Cardiol. 2018 Jul 10. doi: 10.1007/s12350-018-1360-2. [Epub ahead of print]

PMID:
29992525
4.

Lipoprotein(a) and apolipoprotein(a) isoform size: Associations with angiographic extent and severity of coronary artery disease, and carotid artery plaque.

Ooi EM, Ellis KL, Barrett PHR, Watts GF, Hung J, Beilby JP, Thompson PL, Stobie P, McQuillan BM.

Atherosclerosis. 2018 Aug;275:232-238. doi: 10.1016/j.atherosclerosis.2018.06.863. Epub 2018 Jun 18.

PMID:
29960898
5.

The Role of Nutraceuticals in Statin Intolerant Patients.

Banach M, Patti AM, Giglio RV, Cicero AFG, Atanasov AG, Bajraktari G, Bruckert E, Descamps O, Djuric DM, Ezhov M, Fras Z, von Haehling S, Katsiki N, Langlois M, Latkovskis G, Mancini GBJ, Mikhailidis DP, Mitchenko O, Moriarty PM, Muntner P, Nikolic D, Panagiotakos DB, Paragh G, Paulweber B, Pella D, Pitsavos C, Reiner Ž, Rosano GMC, Rosenson RS, Rysz J, Sahebkar A, Serban MC, Vinereanu D, Vrablík M, Watts GF, Wong ND, Rizzo M; International Lipid Expert Panel (ILEP).

J Am Coll Cardiol. 2018 Jul 3;72(1):96-118. doi: 10.1016/j.jacc.2018.04.040. Review.

PMID:
29957236
6.

PCSK9 monoclonal antibody on a knife-edge: An article of faith in FH?

Ward NC, Watts GF.

J Clin Lipidol. 2018 Jul - Aug;12(4):844-848. doi: 10.1016/j.jacl.2018.05.015. Epub 2018 Jun 1. No abstract available.

PMID:
29945779
7.

Squaring up the health economics of PCSK9 monoclonal antibodies 'down under'.

Watts GF, Norman R.

Int J Cardiol. 2018 Sep 15;267:193-194. doi: 10.1016/j.ijcard.2018.06.003. Epub 2018 Jun 2. No abstract available.

PMID:
29887280
8.

Comparative Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition and Statins on Postprandial Triglyceride-Rich Lipoprotein Metabolism.

Chan DC, Watts GF, Somaratne R, Wasserman SM, Scott R, Barrett PHR.

Arterioscler Thromb Vasc Biol. 2018 Jul;38(7):1644-1655. doi: 10.1161/ATVBAHA.118.310882. Epub 2018 Jun 7.

9.

The Present and the Future of Genetic Testing in Familial Hypercholesterolemia: Opportunities and Caveats.

Hooper AJ, Burnett JR, Bell DA, Watts GF.

Curr Atheroscler Rep. 2018 May 19;20(6):31. doi: 10.1007/s11883-018-0731-0. Review.

PMID:
29779130
10.

Fenofibrate effects on carotid artery intima-media thickness in adults with type 2 diabetes mellitus: A FIELD substudy.

Harmer JA, Keech AC, Veillard AS, Skilton MR, Watts GF, Celermajer DS; FIELD Vascular Study Investigators.

Diabetes Res Clin Pract. 2018 Jul;141:156-167. doi: 10.1016/j.diabres.2018.05.006. Epub 2018 May 26.

PMID:
29763709
11.

Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM.

Langlois MR, Chapman MJ, Cobbaert C, Mora S, Remaley AT, Ros E, Watts GF, Borén J, Baum H, Bruckert E, Catapano A, Descamps OS, von Eckardstein A, Kamstrup PR, Kolovou G, Kronenberg F, Langsted A, Pulkki K, Rifai N, Sypniewska G, Wiklund O, Nordestgaard BG; European Atherosclerosis Society (EAS) and the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Joint Consensus Initiative.

Clin Chem. 2018 Jul;64(7):1006-1033. doi: 10.1373/clinchem.2018.287037. Epub 2018 May 14.

PMID:
29760220
12.

Rationale and design of a trial to personalize risk assessment in familial coronary artery disease.

Marwick TH, Whitmore K, Nicholls SJ, Stanton T, Mitchell G, Tonkin A, Blizzard C, Neil A, Jones C, Watts GF; CAUGHT-CAD Investigators.

Am Heart J. 2018 May;199:22-30. doi: 10.1016/j.ahj.2017.09.011. Epub 2017 Sep 19.

PMID:
29754662
13.

Elevated lipoprotein(a) and low-density lipoprotein cholesterol as predictors of the severity and complexity of angiographic lesions in patients with premature coronary artery disease.

Chieng D, Pang J, Ellis KL, Hillis GS, Watts GF, Schultz CJ.

J Clin Lipidol. 2018 Jul - Aug;12(4):1019-1026. doi: 10.1016/j.jacl.2018.03.090. Epub 2018 Apr 3.

PMID:
29703625
14.

Parent-child genetic testing for familial hypercholesterolaemia in an Australian context.

Pang J, Martin AC, Bates TR, Hooper AJ, Bell DA, Burnett JR, Norman R, Watts GF.

J Paediatr Child Health. 2018 Jul;54(7):741-747. doi: 10.1111/jpc.13898. Epub 2018 Apr 6.

PMID:
29626384
15.

Is Lipoprotein(a) Ready for Prime-Time Use in the Clinic?

Ellis KL, Watts GF.

Cardiol Clin. 2018 May;36(2):287-298. doi: 10.1016/j.ccl.2017.12.010. Review.

PMID:
29609758
16.

Health literacy in familial hypercholesterolemia: A cross-national study.

Hagger MS, Hardcastle SJ, Hu M, Kwok S, Lin J, Nawawi HM, Pang J, Santos RD, Soran H, Su TC, Tomlinson B, Watts GF.

Eur J Prev Cardiol. 2018 Jun;25(9):936-943. doi: 10.1177/2047487318766954. Epub 2018 Mar 29.

PMID:
29592531
17.

The effect of n-3 fatty acids and coenzyme Q10 supplementation on neutrophil leukotrienes, mediators of inflammation resolution and myeloperoxidase in chronic kidney disease.

Barden AE, Shinde S, Burke V, Puddey IB, Beilin LJ, Irish AB, Watts GF, Mori TA.

Prostaglandins Other Lipid Mediat. 2018 May;136:1-8. doi: 10.1016/j.prostaglandins.2018.03.002. Epub 2018 Mar 22.

PMID:
29577973
18.

Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics.

Watts GF, Chan DC, Somaratne R, Wasserman SM, Scott R, Marcovina SM, Barrett PHR.

Eur Heart J. 2018 Jul 14;39(27):2577-2585. doi: 10.1093/eurheartj/ehy122.

PMID:
29566128
19.

Elevated lipoprotein(a) and familial hypercholesterolemia in the coronary care unit: Between Scylla and Charybdis.

Ellis KL, Pang J, Chieng D, Bell DA, Burnett JR, Schultz CJ, Hillis GS, Watts GF.

Clin Cardiol. 2018 Mar;41(3):378-384. doi: 10.1002/clc.22880. Epub 2018 Feb 26.

20.

A Comparative Analysis of Phenotypic Predictors of Mutations in Familial Hypercholesterolemia.

Chan DC, Pang J, Hooper AJ, Bell DA, Bates TR, Burnett JR, Watts GF.

J Clin Endocrinol Metab. 2018 Apr 1;103(4):1704-1714. doi: 10.1210/jc.2017-02622.

PMID:
29408959
21.

Nutraceuticals in the management of patients with statin-associated muscle symptoms, with a note on real-world experience.

Ward NC, Pang J, Ryan JDM, Watts GF.

Clin Cardiol. 2018 Jan;41(1):159-165. doi: 10.1002/clc.22862. Epub 2018 Jan 24. Review.

22.

The impact of non-vitamin K antagonist oral anticoagulants (NOACs) on anticoagulation therapy in rural Australia.

Bellinge JW, Paul JJ, Walsh LS, Garg L, Watts GF, Schultz C.

Med J Aust. 2018 Jan 15;208(1):18-23.

PMID:
29320668
23.

Acute Impact of Different Exercise Modalities on Arterial and Platelet Function.

Haynes A, Linden MD, Robey E, Watts GF, Barrett PHR, Naylor LH, Green DJ.

Med Sci Sports Exerc. 2018 Apr;50(4):785-791. doi: 10.1249/MSS.0000000000001505.

PMID:
29240651
24.

Reverse cascade screening for familial hypercholesterolemia in high-risk Chinese families.

Wu X, Pang J, Wang X, Peng J, Chen Y, Wang S, Watts GF, Lin J.

Clin Cardiol. 2017 Nov;40(11):1169-1173. doi: 10.1002/clc.22809. Epub 2017 Nov 23.

25.

Effects of Allopurinol on Endothelial Function: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials.

Cicero AFG, Pirro M, Watts GF, Mikhailidis DP, Banach M, Sahebkar A.

Drugs. 2018 Jan;78(1):99-109. doi: 10.1007/s40265-017-0839-5. Review.

PMID:
29139092
26.

Lipoprotein apheresis downregulates IL-1α, IL-6 and TNF-α mRNA expression in severe dyslipidaemia.

Stefanutti C, Mazza F, Pasqualetti D, Di Giacomo S, Watts GF, Massari MS, de Neve J, Morozzi C, Fischer M.

Atheroscler Suppl. 2017 Nov;30:200-208. doi: 10.1016/j.atherosclerosissup.2017.05.028.

PMID:
29096839
27.

The Role of Sympatho-Inhibition in Combination Treatment of Obesity-Related Hypertension.

Carnagarin R, Gregory C, Azzam O, Hillis GS, Schultz C, Watts GF, Bell D, Matthews V, Schlaich MP.

Curr Hypertens Rep. 2017 Oct 28;19(12):99. doi: 10.1007/s11906-017-0795-1. Review.

PMID:
29080925
28.

An enquiry based on a standardised questionnaire into knowledge, awareness and preferences concerning the care of familial hypercholesterolaemia among primary care physicians in the Asia-Pacific region: the "Ten Countries Study".

Pang J, Hu M, Lin J, Miida T, Nawawi HM, Park JE, Wu X, Ramli AS, Kim NT, Kwok S, Gonzalez-Santos LE, Su TC, Truong TH, Soran H, Yamashita S, Tomlinson B, Watts GF.

BMJ Open. 2017 Oct 25;7(10):e017817. doi: 10.1136/bmjopen-2017-017817.

29.

Detection and management of familial hypercholesterolaemia in primary care in Australia: protocol for a pragmatic cluster intervention study with pre-post intervention comparisons.

Arnold-Reed DE, Brett T, Troeung L, Vickery A, Garton-Smith J, Bell D, Pang J, Grace T, Bulsara C, Li I, Bulsara M, Watts GF.

BMJ Open. 2017 Oct 22;7(10):e017539. doi: 10.1136/bmjopen-2017-017539.

30.

The shape of things to come in lipid management: a feast of reason.

Watts GF, Stroes ESG.

Curr Opin Lipidol. 2017 Dec;28(6):449-451. doi: 10.1097/MOL.0000000000000467. No abstract available.

PMID:
29035915
31.

Depicting new pharmacological strategies for familial hypercholesterolaemia involving lipoprotein (a).

Vuorio A, Watts GF, Kovanen PT.

Eur Heart J. 2017 Dec 21;38(48):3555-3559. doi: 10.1093/eurheartj/ehx546.

PMID:
29029165
32.

Comprehending the Health Informatics Spectrum: Grappling with System Entropy and Advancing Quality Clinical Research.

Bellgard MI, Chartres N, Watts GF, Wilton S, Fletcher S, Hunter A, Snelling T.

Front Public Health. 2017 Sep 14;5:224. doi: 10.3389/fpubh.2017.00224. eCollection 2017. No abstract available.

33.

The renaissance of lipoprotein(a): Brave new world for preventive cardiology?

Ellis KL, Boffa MB, Sahebkar A, Koschinsky ML, Watts GF.

Prog Lipid Res. 2017 Oct;68:57-82. doi: 10.1016/j.plipres.2017.09.001. Epub 2017 Sep 6. Review.

PMID:
28888913
35.

Optimizing Cholesterol Treatment in Patients With Muscle Complaints.

Rosenson RS, Baker S, Banach M, Borow KM, Braun LT, Bruckert E, Brunham LR, Catapano AL, Elam MB, Mancini GBJ, Moriarty PM, Morris PB, Muntner P, Ray KK, Stroes ES, Taylor BA, Taylor VH, Watts GF, Thompson PD.

J Am Coll Cardiol. 2017 Sep 5;70(10):1290-1301. doi: 10.1016/j.jacc.2017.07.752. Review.

36.

World Heart Federation Cholesterol Roadmap.

Murphy A, Faria-Neto JR, Al-Rasadi K, Blom D, Catapano A, Cuevas A, Lopez-Jimenez F, Perel P, Santos R, Sniderman A, Sy R, Watts GF, Zhao D, Yusuf S, Wood D.

Glob Heart. 2017 Sep;12(3):179-197.e5. doi: 10.1016/j.gheart.2017.03.002. Epub 2017 Jul 29. Review.

PMID:
28765036
37.

PCSK9 in context: A contemporary review of an important biological target for the prevention and treatment of atherosclerotic cardiovascular disease.

Page MM, Watts GF.

Diabetes Obes Metab. 2018 Feb;20(2):270-282. doi: 10.1111/dom.13070. Epub 2017 Aug 30. Review.

PMID:
28736830
38.

The evolving model of care for familial hypercholesterolaemia.

Watts GF, Pang J.

Eur J Prev Cardiol. 2017 Nov;24(16):1729-1732. doi: 10.1177/2047487317721656. Epub 2017 Jul 18. No abstract available.

PMID:
28718675
39.

Structural determination of lipid antigens captured at the CD1d-T-cell receptor interface.

Brennan PJ, Cheng TY, Pellicci DG, Watts GFM, Veerapen N, Young DC, Rossjohn J, Besra GS, Godfrey DI, Brenner MB, Moody DB.

Proc Natl Acad Sci U S A. 2017 Aug 1;114(31):8348-8353. doi: 10.1073/pnas.1705882114. Epub 2017 Jul 17.

40.

Knowns and unknowns in the care of pediatric familial hypercholesterolemia.

Martin AC, Gidding SS, Wiegman A, Watts GF.

J Lipid Res. 2017 Sep;58(9):1765-1776. doi: 10.1194/jlr.S074039. Epub 2017 Jul 12. Review.

41.

Response by Watts et al to Letter Regarding Article, "Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein Metabolism".

Watts GF, Chan DC, Somaratne R, Wasserman SM, Sabatine MS.

Circulation. 2017 Jul 4;136(1):120-121. doi: 10.1161/CIRCULATIONAHA.117.028790. No abstract available.

PMID:
28674100
42.

Impact of consumer copayments for subsidised medicines on health services use and outcomes: a protocol using linked administrative data from Western Australia.

Seaman KL, Sanfilippo FM, Roughead EE, Bulsara MK, Kemp-Casey A, Bulsara C, Watts GF, Preen D.

BMJ Open. 2017 Jun 21;7(6):e013691. doi: 10.1136/bmjopen-2016-013691.

43.

Detection of atherosclerotic cardiovascular disease influences the perceived need for aggressive lipid management.

Mancini GBJ, Gupta M, Tsigoulis M, Cannon CP, Genest J, Ray KK, Santos RD, Watts GF, Raggi P.

Atherosclerosis. 2017 Aug;263:112-118. doi: 10.1016/j.atherosclerosis.2017.06.006. Epub 2017 Jun 3.

44.

Toward an international consensus-Integrating lipoprotein apheresis and new lipid-lowering drugs.

Stefanutti C, Julius U, Watts GF, Harada-Shiba M, Cossu M, Schettler VJ, De Silvestro G, Soran H, Van Lennep JR, Pisciotta L, Klör HU, Widhalm K, Moriarty PM; MIGHTY MEDIC Multinational Society.

J Clin Lipidol. 2017 Jul - Aug;11(4):858-871.e3. doi: 10.1016/j.jacl.2017.04.114. Epub 2017 Apr 25. Review.

45.

Detecting familial hypercholesterolemia: The Jack and the Beanstalk principle.

Martin AC, Allen C, Pang J, Watts GF.

J Clin Lipidol. 2017 Mar - Apr;11(2):575-578. doi: 10.1016/j.jacl.2017.02.003. Epub 2017 Feb 22.

PMID:
28502516
46.

New data on familial hypercholesterolaemia and acute coronary syndromes: The promise of PCSK9 monoclonal antibodies in the light of recent clinical trials.

Ellis KL, Pang J, Schultz CJ, Watts GF.

Eur J Prev Cardiol. 2017 Jul;24(11):1200-1205. doi: 10.1177/2047487317708890. Epub 2017 May 9. Review.

PMID:
28482694
47.

Mode of action of berberine on lipid metabolism: a new-old phytochemical with clinical applications?

Sahebkar A, Watts GF.

Curr Opin Lipidol. 2017 Jun;28(3):282-283. doi: 10.1097/MOL.0000000000000409. No abstract available.

PMID:
28459766
48.

Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel.

Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, Hegele RA, Krauss RM, Raal FJ, Schunkert H, Watts GF, Borén J, Fazio S, Horton JD, Masana L, Nicholls SJ, Nordestgaard BG, van de Sluis B, Taskinen MR, Tokgözoglu L, Landmesser U, Laufs U, Wiklund O, Stock JK, Chapman MJ, Catapano AL.

Eur Heart J. 2017 Aug 21;38(32):2459-2472. doi: 10.1093/eurheartj/ehx144. Review.

49.

Novel protein biomarkers associated with coronary artery disease in statin-treated patients with familial hypercholesterolemia.

Bos S, Phillips M, Watts GF, Verhoeven AJM, Sijbrands EJG, Ward NC.

J Clin Lipidol. 2017 May - Jun;11(3):682-693. doi: 10.1016/j.jacl.2017.03.014. Epub 2017 Apr 4.

PMID:
28434814
50.

Beyond cascade screening: detection of familial hypercholesterolaemia at childhood immunization and other strategies.

Martin AC, Bell DA, Brett T, Watts GF.

Curr Opin Lipidol. 2017 Aug;28(4):321-327. doi: 10.1097/MOL.0000000000000423. Review.

PMID:
28426524

Supplemental Content

Loading ...
Support Center